LAVA Therapeutics N.V.
LVTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $25,520 | $42,237 | $90,734 | $108,670 |
| - Cash | $35,015 | $44,231 | $100,333 | $151,014 |
| + Debt | $5,281 | $6,313 | $5,450 | $5,516 |
| Enterprise Value | -$4,214 | $4,319 | -$4,149 | -$36,828 |
| Revenue | $11,982 | $6,769 | $19,391 | $5,350 |
| % Growth | 77% | -65.1% | 262.4% | – |
| Gross Profit | $11,982 | $3,287 | $19,391 | $5,350 |
| % Margin | 100% | 48.6% | 100% | 100% |
| EBITDA | -$23,502 | -$40,532 | -$30,795 | -$41,015 |
| % Margin | -196.1% | -598.8% | -158.8% | -766.6% |
| Net Income | -$25,114 | -$41,871 | -$31,907 | -$42,355 |
| % Margin | -209.6% | -618.6% | -164.5% | -791.7% |
| EPS Diluted | -0.94 | -1.57 | -1.23 | -2.14 |
| % Growth | 40.1% | -27.6% | 42.5% | – |
| Operating Cash Flow | -$19,544 | -$40,283 | $4,043 | -$28,647 |
| Capital Expenditures | -$23 | -$731 | -$587 | -$764 |
| Free Cash Flow | -$19,567 | -$41,014 | $3,456 | -$29,411 |